Log In
BCIQ
Print this Print this
 

PegIntron/Rebetol Combination Therapy (peginterferon alfa-2b/ribavirin)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionPegylated recombinant interferon (IFN) alfa-2b combined with a nucleoside analog
Molecular Target Type I interferon (IFN) receptor
Mechanism of ActionType I interferon (IFN) receptor agonist
Therapeutic ModalityBiologic
Latest Stage of DevelopmentApproved
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat hepatitis C virus (HCV) genotype 1 infection in non-responders; Treat hepatitis C virus (HCV) genotype 1 infection in slow responders; Treat hepatitis C virus (HCV) infection; Treat hepatitis C virus (HCV) infection in patients co-infected with HIV
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today